Literature DB >> 17310874

Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers.

Mahesh Kudrimoti1, Eun Young Lee, Yuna Kang, Mansoor Ahmed, Mohammed Mohiuddin.   

Abstract

PURPOSE: Pre-operative induction chemoradiotherapy has been used to downstage advanced rectal cancers. The variation in response rates is believed to be not only dependent on tumor size but also on the biological properties of individual tumors.
METHODS: We evaluated 17 rectal cancer patients treated with induction 5 Fluorouracil-based chemoradiotherapy and subsequent surgery. The pre-treatment biopsy specimens of these patients were analyzed with antibodies to Ki-67, p53, p21(wafl/cipl) MDM-2 and BCL-2 using an avidinbiotinylated peroxidase technique.
RESULTS: There were 5 patients with a complete response and 12 patients with a partial response. The overall expression of Ki-67 was 100%, p53-76%, p21(Wafl/cip) -64%, MDM-2-47%, and BCL-2-60%. Among the complete responders the expression was 100%, 80%, 60%, 20%, and 60%, respectively, whereas among the partial responders it was 100%, 75%, 67%, 57%,, and 16%, respectively. We found the expression of BCL2 was the only significant predictor of response to preoperative chemoradiation.
CONCLUSIONS: The immunohistochemical analysis for Ki-67, p53, p21(waf1/cip1), and MDM-2 in pretreatment biopsy specimens of rectal cancer is not useful in predicting response to induction chemoradiotherapy in rectal cancers. BCL-2 expression was highly statistically significant for complete response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310874

Source DB:  PubMed          Journal:  J Ky Med Assoc        ISSN: 0023-0294


  7 in total

Review 1.  Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-06-16       Impact factor: 2.549

2.  Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy.

Authors:  Taek-Keun Nam; Ji-Shin Lee; Hyeong-Rok Kim; Sung-Ja Ahn; Ju-Young Song; Mee Sun Yoon
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

3.  The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer.

Authors:  Jonathan M Hernandez; Whalen Clark; Jill Weber; William J Fulp; Lauren Lange; David Shibata
Journal:  Int J Colorectal Dis       Date:  2014-06-27       Impact factor: 2.571

4.  A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial.

Authors:  Masafumi Inomata; Tomonori Akagi; Kentaro Nakajima; Tsuyoshi Etoh; Koichiro Tahara; Toshifumi Matsumoto; Tadashi Ogawa; Kyuzo Fujii; Akio Shiromizu; Seigo Kitano
Journal:  Mol Clin Oncol       Date:  2016-02-04

5.  Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer.

Authors:  Hyuk Hur; Min Soo Cho; Woong Sub Koom; Joon Seok Lim; Tae Il Kim; Joong Bae Ahn; Hoguen Kim; Nam Kyu Kim
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

Review 6.  New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer.

Authors:  Nam Kyu Kim; Hyuk Hur
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

7.  Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.

Authors:  Gaya Spolverato; Salvatore Pucciarelli; Roberta Bertorelle; Anita De Rossi; Donato Nitti
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.